Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial Prof Luis Rivera, MD, Rasmus S Pedersen, PhD, Lourdes Peña, MD, Klaus J Olsen, PhD, Lars V Andreasen, PhD, Ingrid Kromann, BSc, Pernille I Nielsen, MSc, Charlotte Sørensen, MSc, Jes Dietrich, PhD, Ananda S Bandyopadhyay, MBBS, Birgit Thierry-Carstensen, MSc The Lancet Infectious Diseases Volume 17, Issue 7, Pages 745-753 (July 2017) DOI: 10.1016/S1473-3099(17)30177-9 Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure Trial profile All vaccines were manufactured by SSI. FAS=full analysis set. IPV=inactivated polio vaccine. IPV-Al=IPV adsorbed to aluminium hydroxide. PP=per-protocol. The Lancet Infectious Diseases 2017 17, 745-753DOI: (10.1016/S1473-3099(17)30177-9) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions